Abstract
The deregulated tyrosine kinase activity of the Bcr-Abl fusion protein has been established as the causative molecular event in chronic myelogenous leukemia (CML). Thus the Bcr-Abl tyrosine kinase is an ideal target for pharmacologic inhibition. STI571 (formerly CGP57148B), is an Abl-specific tyrosine kinase inhibitor that in preclinical studies selectively kills Bcr-Abl-containing cells in vitro and in vivo. The results of clinical studies have demonstrated the potential of molecularly targeted therapies, and STI571 is emerging as a new therapeutic agent for CML.
Original language | English (US) |
---|---|
Pages (from-to) | S77-S78 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 48 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - 2001 |
Keywords
- Bcr-Abl
- Chronic myelogenous leukemia
- ST1571
- Targeted therapy
- Tyrosine kinase
ASJC Scopus subject areas
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)